Ranbaxy Laboratories, which received the USFDA nod, has announced that it will launch its generic formulation of Clarithromycin immediate release (IR) tablets, 250 mg and 500 mg, in the US, on May 24, 2005.
According to a release issued by Ranbaxy to the BSE, the company's Clarithromycin tablets will be manufactured and marketed under the Ranbaxy label. The total annual market sales for 250 mg and 500 mg of Biaxin Filmtab were $204.3 million.
Jim Meehan, VP of sales and marketing for Ranbaxy Pharma stated, "We are delighted to market this product as an addition to our ever growing generic product portfolio. Our plans are to bring this product to the market immediately."
Content Guide
